Intellia has received a grant from the Bill & Melinda Gates Foundation to develop curative CRISPR/Cas9 in vivo sickle cell disease treatments. Read more.

Funding will be used to develop safe, scalable and accessible non-viral treatments for sickle cell patients.

“Have you ever been in an environment full of intellectual people? Now combine that with CRISPR/Cas9. Greatness at full potential.”

Denisse
Sr. Associate Scientist, Mass Spectrometry

“UKATPA’s objective is to raise awareness and give support to patients, caregivers and health care professionals.”

Vince
UKATPA Treasurer

Vince and David, friends and colleagues living with ATTR

“The biggest surprise to us was how many people have amyloidosis and don’t have anyone to talk to.”
– David, UKATPA Secretary

Read more

The 2020 Nobel Prize in Chemistry has been awarded “for the development of a method for genome editing.”

Jennifer Doudna, Ph.D.
Co-founder, Intellia Therapeutics

“My father-in-law, Ben – or as Pam calls him, Benny – lost his battle with AML far too soon, which makes me especially proud to work for a company that is striving to provide curative treatments for that disease, among others.”

Stacey
Associate Director, Finance
Pam, whose husband passed away from acute myeloid leukemia

“Benny had a way of making everything OK. I miss his smile.”

Read more
Overview

Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.

Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.

Programs & Pipeline

Each one of us together for patients

We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.

Join Us.
See how you can change life stories with genome editing
Follow Us on Social Media
May 11, 2021

Later today, Intellia Vice President, Disease Biology, Sean Burns, M.D., will be presenting at #ASGCT21 about #alpha1 at 5:30 p.m. ET during the Delivery Technologies and #CRISPR for Therapeutics session. #AATD @ASGCTherapy https://t.co/1KKSj3ckIn

May 11, 2021

Today, Intellia CSO, @LauraSeppLore, will be at #ASGCT21 speaking about in vivo #CRISPR-based therapeutics during the #GenomeEditing Clinical and Preclinical Updates session. Be sure to tune in! @ASGCTherapy https://t.co/dpkltrcX3y

Menu